Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 29, 2016

Primary Completion Date

August 15, 2019

Study Completion Date

August 15, 2019

Conditions
Amyotrophic Lateral Sclerosis
Interventions
BIOLOGICAL

Albutein 5%

Albutein is manufactured from human plasma. The dose of Albutein 5% for replacement following plasma removal will be calculated based on gender, weight, and the hematocrit of the participant.

PROCEDURE

Plasma Exchange

Plasma Exchange will be performed using albutein 5% as the replacement solution.

Trial Locations (1)

03756

Dartmouth-Hitchcock Medical Center, Lebanon

Sponsors
All Listed Sponsors
collaborator

Grifols Biologicals, LLC

INDUSTRY

lead

Grifols Therapeutics LLC

INDUSTRY